Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
The purpose of this study is to study the safety and efficacy of chemotherapy usage followed
 by CIK transfusion in refractory and/or chemoresistant lymphomas.
Autologous cytokine-induced killer (CIK) cells transfusion(>2*10^9 cells count) within 2
 weeks after regular chemotherapy every 3 months.
Inclusion Criteria:

 -  diagnosed as non-Hodgkin lymphoma with negative effect of regular chemotherapy, and
 need further therapy

 Exclusion Criteria:

 -  patients refuse the therapy or have no tolerance for the therapy